Delving into the Latest Updates on IriSys, Inc. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

TLR7(Toll like receptor 7)	1

主要目的： 1) 评估CAN1012注射液在晚期实体瘤患者中的安全性和耐受性； 2) 确定最大耐受剂量（MTD）和/或Ⅱ期推荐剂量（RP2D）。次要目的： 1) 评估CAN1012注射液在晚期实体瘤患者中的药代动力学（PK）特征； 2) 评估CAN1012注射液在晚期实体瘤患者中的初步有效性。探索性目的： 1) 评估CAN1012注射液在晚期实体瘤患者中的药效动力学（PD）特征； 2) 探索生物标志物（包括CD3、CD8、PD-L1、BDCA2）与CAN1012注射液有效性的相关性。

[Translation]

Primary objectives: 1) To evaluate the safety and tolerability of CAN1012 injection in patients with advanced solid tumors; 2) To determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D). Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of CAN1012 injection in patients with advanced solid tumors; 2) To evaluate the preliminary efficacy of CAN1012 injection in patients with advanced solid tumors. Exploratory objectives: 1) To evaluate the pharmacodynamic (PD) characteristics of CAN1012 injection in patients with advanced solid tumors; 2) To explore the correlation between biomarkers (including CD3, CD8, PD-L1, BDCA2) and the efficacy of CAN1012 injection.

Start Date09 Sep 2022

Sponsor / Collaborator

Conway (Guangzhou) Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with IriSys, Inc.

Login to view more data

0 Patents (Medical) associated with IriSys, Inc.

Login to view more data

100 Deals associated with IriSys, Inc.

Login to view more data

100 Translational Medicine associated with IriSys, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data